Therapy News and Research

RSS

UMSOM researchers to test the safety, tolerability of prototype Shigella-ETEC vaccine

Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli, and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.

10 Dec 2019

Huntington's disease patients need to better understand the risks and benefits of new therapies

For patients with Huntington's disease (HD), clinical trials can offer hope when there are no treatments available despite unknowns about whether the therapy will work or is safe.

10 Dec 2019

Study focuses on smoking cessation treatment for adolescents

Preventable deaths are those that can be stymied by public health intervention, and deaths related to tobacco use are at the top of that list in the United States as well as globally.

10 Dec 2019

New joint venture aims to develop implantable cell therapies for debilitating conditions with no cure

Mayo Clinic and W. L. Gore & Associates Inc., a global materials science company, have formed a joint venture to advance the development of implantable cell therapies to treat debilitating conditions with no cure. Avobis Bio will combine Mayo Clinic's clinical and cell expertise and Gore's expertise in material sciences to address some of the most challenging medical issues.

10 Dec 2019

Study provides most detailed classification of acute myeloid leukemia, myelodysplastic syndrome

Results from a study conducted by St. Jude Children's Research Hospital and the Munich Leukemia Laboratory were presented today as a late-breaking abstract at the American Society of Hematology annual meeting. The study integrates genomic and transcriptomic sequencing to provide the most detailed classification of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) to date.

10 Dec 2019

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.

10 Dec 2019

Immunotherapy more effective than chemotherapy for children, young adults with relapsed B-ALL

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.

10 Dec 2019

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Scientists will present more than 40 abstracts highlighting research driven in part by Bio-Rad Laboratories' Droplet Digital PCR (ddPCR) technology at the 2019 American Society of Hematology (ASH) meeting in Orlando Florida, December 7-10.

10 Dec 2019

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.

10 Dec 2019

Rutgers researchers identify small mutations for AML and MDS through deep DNA sequencing

Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations.

9 Dec 2019

Retrospective review: Proton therapy well tolerated in patients undergoing breast conserving surgery

While the assessment of proton therapy in breast cancer treatment continues through clinical trials, data relating to early toxicity and cosmetic outcomes for this population are limited.

9 Dec 2019

Common antibiotic appears to boost the effect of radiation on tumor cells

The antibiotic vancomycin alters the gut microbiome in a way that can help prime the immune system to more effectively attack tumor cells after radiation therapy.

9 Dec 2019

Experts publish new book with recommendations to reduce Latino cancer

As U.S. Latinos face a staggering 142% projected rise in cancer cases by 2030, UT Health San Antonio leaders gathered international cancer experts to publish a new book with innovative research and recommendations to reduce Latino cancer.

9 Dec 2019

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

9 Dec 2019

New nanoparticle innovation detects vascular calcification in atherosclerosis

Heart disease and stroke are the world's two most deadly diseases, causing over 15 million deaths in 2016 according to the World Health Organization.

9 Dec 2019

Pairing chemotherapy azacitidine with enasidenib boosts complete remission in AML patients

A multi-institutional, Phase II study led by The University of Texas MD Anderson Cancer Center showed that pairing standard chemotherapy azacitidine (AZA) with a drug called enasidenib (ENA) measurably boosts complete remission in patients newly diagnosed with a specific form of acute myeloid leukemia (AML).

9 Dec 2019

Innovative experimental therapy may stop growth of triple-negative breast cancer

Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.

9 Dec 2019

Yale study highlights the need to develop effective, less toxic approaches to treat AML patients

A new study by Yale Cancer Center researchers shows understanding treatment patterns for patients with acute myeloid leukemia is vital to develop strategies to improve outcomes.

9 Dec 2019

Study shows how a new combination approach helps overcome resistance to cancer immunotherapy

Cancer immunology drugs, which harness the body's immune system to better attack cancer cells, have significantly changed the face of cancer treatment. People with aggressive cancers are now living longer, healthier lives. Unfortunately, cancer immunology therapy only works in a subset of patients.

9 Dec 2019

Therapy News and Research

UMSOM researchers to test the safety, tolerability of prototype Shigella-ETEC vaccine

Huntington's disease patients need to better understand the risks and benefits of new therapies

Study focuses on smoking cessation treatment for adolescents

New joint venture aims to develop implantable cell therapies for debilitating conditions with no cure

Study provides most detailed classification of acute myeloid leukemia, myelodysplastic syndrome

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Immunotherapy more effective than chemotherapy for children, young adults with relapsed B-ALL

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

Rutgers researchers identify small mutations for AML and MDS through deep DNA sequencing

Retrospective review: Proton therapy well tolerated in patients undergoing breast conserving surgery

Common antibiotic appears to boost the effect of radiation on tumor cells

Experts publish new book with recommendations to reduce Latino cancer

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

New nanoparticle innovation detects vascular calcification in atherosclerosis

Pairing chemotherapy azacitidine with enasidenib boosts complete remission in AML patients

Innovative experimental therapy may stop growth of triple-negative breast cancer

Yale study highlights the need to develop effective, less toxic approaches to treat AML patients

Study shows how a new combination approach helps overcome resistance to cancer immunotherapy

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News